Next Article in Journal
The Lived Experience of Chronic Hepatitis B: A Broader View of Its Impacts and Why We Need a Cure
Next Article in Special Issue
The Effects of Pre-Existing Antibodies on Live-Attenuated Viral Vaccines
Previous Article in Journal
Protocol and Reagents for Pseudotyping Lentiviral Particles with SARS-CoV-2 Spike Protein for Neutralization Assays
Open AccessArticle

Transcutaneous Administration of Dengue Vaccines

1
Vaccine Development Laboratory, Microbiology Department, Institute of Biomedical Sciences, University of São Paulo, São Paulo 05508-000, Brazil
2
Center for Biological and Health Sciences, Federal University of Western Bahia, Bahia 47810-047, Brazil
*
Author to whom correspondence should be addressed.
Viruses 2020, 12(5), 514; https://doi.org/10.3390/v12050514
Received: 3 February 2020 / Revised: 26 March 2020 / Accepted: 3 April 2020 / Published: 6 May 2020
(This article belongs to the Special Issue Flavivirus Vaccines)
In the present study, we evaluated the immunological responses induced by dengue vaccines under experimental conditions after delivery via a transcutaneous (TC) route. Vaccines against type 2 Dengue virus particles (DENV2 New Guinea C (NGC) strain) combined with enterotoxigenic Escherichia coli (ETEC) heat-labile toxin (LT) were administered to BALB/c mice in a three-dose immunization regimen via the TC route. As a control for the parenteral administration route, other mouse groups were immunized with the same vaccine formulation via the intradermic (ID) route. Our results showed that mice vaccinated either via the TC or ID routes developed similar protective immunity, as measured after lethal challenges with the DENV2 NGC strain. Notably, the vaccine delivered through the TC route induced lower serum antibody (IgG) responses with regard to ID-immunized mice, particularly after the third dose. The protective immunity elicited in TC-immunized mice was attributed to different antigen-specific antibody properties, such as epitope specificity and IgG subclass responses, and cellular immune responses, as determined by cytokine secretion profiles. Altogether, the results of the present study demonstrate the immunogenicity and protective properties of a dengue vaccine delivered through the TC route and offer perspectives for future clinical applications. View Full-Text
Keywords: transcutaneous immunization; dengue vaccines; heat-labile toxin; adjuvant; intradermic immunization transcutaneous immunization; dengue vaccines; heat-labile toxin; adjuvant; intradermic immunization
Show Figures

Figure 1

MDPI and ACS Style

Andreata-Santos, R.; Alves, R.P.S.; Pereira, S.A.; Pereira, L.R.; Freitas, C.L.; Pereira, S.S.; Venceslau-Carvalho, A.A.; Castro-Amarante, M.F.; Favaro, M.T.P.; Mathias-Santos, C.; Amorim, J.H.; Ferreira, L.C.S. Transcutaneous Administration of Dengue Vaccines. Viruses 2020, 12, 514.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop